Journal of Cancer Metastasis and Treatment最新文献_第8页

Journal of Cancer Metastasis and Treatment Pub Date : 2022-01-01 DOI: 10.20517/2394-4722.2022.49

Y. Yonemura, H. Ishibashi, A. Mizumoto, T. Fujita, Yang Liu, S. Wakama, Syouzou Sako, N. Takao, Toshiyuki Kitai, K. Katayama, Y. Kamada, K. Taniguchi, Daisuke Fujimoto

{"title":"Peritoneal mesothelioma","authors":"Y. Yonemura, H. Ishibashi, A. Mizumoto, T. Fujita, Yang Liu, S. Wakama, Syouzou Sako, N. Takao, Toshiyuki Kitai, K. Katayama, Y. Kamada, K. Taniguchi, Daisuke Fujimoto","doi":"10.20517/2394-4722.2022.49","DOIUrl":"https://doi.org/10.20517/2394-4722.2022.49","url":null,"abstract":"This review provides an overview of articles about peritoneal mesothelioma (PM) to analyze the effect of treatment modalities on response rates, post-treatment side effects, morbidity and mortality, and survival. Median survival in months following systemic chemotherapy (SC) ranged from 8.7 to 26.8 months. However, no patient was reported to have survived for more than five years with SC alone. In contrast, comprehensive treatment that included cytoreductive surgery (CRS) + perioperative chemotherapy (POC) showed a significantly longer median survival time than SC alone. Additionally, CRS + POC demonstrated 10-year survival rates of 12%-35%. Accordingly, CRS + POC is an innovative treatment that provides long-term survival in selected patients with PM. Selection criteria are performance status (ECOG PS ≤ 1), the absence of extraperitoneal metastasis, PCI less than cutoff levels (from < 10 to < 28), MIB-1 index (< 10), and histologic type (epithelioid type). Postoperative morbidity and mortality rates after CRS + POC were significantly higher than with more conventional operations. Accordingly, CRS and POC should be done at the specialized peritoneal surface malignancy centers.","PeriodicalId":15167,"journal":{"name":"Journal of Cancer Metastasis and Treatment","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67652190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The heterogeneity of CAFs and immune cell populations in the tumor microenvironment of pancreatic adenocarcinoma 胰腺腺癌肿瘤微环境中cas和免疫细胞群的异质性

Journal of Cancer Metastasis and Treatment Pub Date : 2022-01-01 DOI: 10.20517/2394-4722.2022.60

M. Diab, B. El-Rayes

{"title":"The heterogeneity of CAFs and immune cell populations in the tumor microenvironment of pancreatic adenocarcinoma","authors":"M. Diab, B. El-Rayes","doi":"10.20517/2394-4722.2022.60","DOIUrl":"https://doi.org/10.20517/2394-4722.2022.60","url":null,"abstract":"Over the past decade, researchers have identified and characterized the diverse cell populations within the tumor microenvironment of pancreatic cancer. The interplay between these cells in the TME either promotes or inhibits the malignant behavior of pancreatic cancer cells. Cancer-associated fibroblasts, previously thought to be one main subset, can now be broadly subclassified into three main types: inflammatory, myofibroblastic, and antigen-presenting, with the former and the latter two exerting pro-tumoral and anti-tumoral functions, respectively. Myeloid cells include myeloid-derived suppressor cells and tumor-associated macrophages. Myeloid-derived suppressor cells can be further divided into polymorphonuclear and monocytic and exhibit pro-tumoral activities. Tumor-associated macrophages exhibit M1 (anti-tumoral) or M2 (pro-tumoral) phenotypes, which are present in a dynamic fashion between the two phenotypes. Other constituents of the immune make-up of the tumor microenvironment include T and B cells and less described subsets which include natural killer cells, γδ T cells, and group 2 innate lymphoid cells. This review provides an overview of the studies that lead to the discovery of those cellular populations and highlights the recent efforts to utilize them as therapeutic targets in pancreatic cancer.","PeriodicalId":15167,"journal":{"name":"Journal of Cancer Metastasis and Treatment","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67652379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

The role of radiotherapy in metastatic bladder cancer 放疗在转移性膀胱癌中的作用

Journal of Cancer Metastasis and Treatment Pub Date : 2022-01-01 DOI: 10.20517/2394-4722.2021.167

J. Perera, P. Hoskin

引用次数: 0

Diagnostic accuracy of MRI and PET/CT for neck staging prior to salvage total laryngectomy 补救性全喉切除术前MRI和PET/CT对颈部分期的诊断准确性

Journal of Cancer Metastasis and Treatment Pub Date : 2022-01-01 DOI: 10.20517/2394-4722.2022.19

Jonas Galli, R. Giger, O. Eliçin, Martin Wartenberg, L. Anschuetz, L. Nisa

{"title":"Diagnostic accuracy of MRI and PET/CT for neck staging prior to salvage total laryngectomy","authors":"Jonas Galli, R. Giger, O. Eliçin, Martin Wartenberg, L. Anschuetz, L. Nisa","doi":"10.20517/2394-4722.2022.19","DOIUrl":"https://doi.org/10.20517/2394-4722.2022.19","url":null,"abstract":"Aim: Lymph node (LN) metastases are associated with poor outcomes in patients with recurrent larynx squamous cell carcinoma (LSCC). Neck dissection (ND) is therefore commonly performed along with salvage total laryngectomy (STL). Here, we assess the rate of occult LN metastases and the diagnostic value of MRI and PET/CT for detecting them in recurrent LSCC. Methods: This retrospective study included patients with recurrent LSCC after primary (chemo)radiotherapy [(C)RT] who were re-staged by MRI and/or PET/CT and treated with STL and ND between 2004 and 2019. The histopathology of ND samples was used as the reference standard. Results: Forty-one patients were included. The prevalence of occult metastases in MRI-negative and PET/CT-negative neck nodes was between 3.2% and 6.1%. Negative predictive values of neck node re-staging were 93.9% for MRI, 96.8% for PET/CT, and 96.2% for MRI and PET/CT combined. Conclusion: Both MRI and PET/CT afforded good negative predictive values for nodal staging in patients with recurrent LSCC after (C)RT prior to STL. In selected patients, these radiological modalities, particularly PET/CT, could help to avoid unnecessary surgery to the neck and its associated morbidity.","PeriodicalId":15167,"journal":{"name":"Journal of Cancer Metastasis and Treatment","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67652283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A shifting adversary: control of pancreatic cancer transcriptomic subtypes 转移的对手:胰腺癌转录组亚型的控制

Journal of Cancer Metastasis and Treatment Pub Date : 2022-01-01 DOI: 10.20517/2394-4722.2022.71

C. David

引用次数: 0

Treatment strategies in cervical cancer: treatment of advanced disease 宫颈癌的治疗策略:晚期疾病的治疗

Journal of Cancer Metastasis and Treatment Pub Date : 2022-01-01 DOI: 10.20517/2394-4722.2022.34

A. Valdivia, Juan Francisco Grau-Béjar, C. García-Durán, A. Oaknin

引用次数: 4

Immunotherapy in malignant pleural mesothelioma: a long story ended in success 恶性胸膜间皮瘤的免疫治疗:一个漫长的故事以成功告终

Journal of Cancer Metastasis and Treatment Pub Date : 2022-01-01 DOI: 10.20517/2394-4722.2022.78

Alberto Bongiovanni, A. Frassoldati, L. Calabrò

引用次数: 1

New developments in management of metastatic thyroid cancer 转移性甲状腺癌治疗的新进展

Journal of Cancer Metastasis and Treatment Pub Date : 2022-01-01 DOI: 10.20517/2394-4722.2021.156

J. Hershman

引用次数: 0

Angiogenesis and osteopontin expression in paraskeletal myeloma with plasmablastic morphology and aggressive clinical course: a report of two cases 血管生成和骨桥蛋白表达在伴浆母细胞形态和侵袭性临床过程的副骨骼骨髓瘤:附2例报告

Journal of Cancer Metastasis and Treatment Pub Date : 2022-01-01 DOI: 10.20517/2394-4722.2021.208

T. Valković, Marija Stanić Damić, Frane Valković, N. Jonjić

引用次数: 0

The role of systemic therapy in borderline resectable and locally advanced pancreatic ductal adenocarcinoma 全身治疗在边缘可切除和局部晚期胰腺导管腺癌中的作用

Journal of Cancer Metastasis and Treatment Pub Date : 2022-01-01 DOI: 10.20517/2394-4722.2022.48

V. Lo, R. Goodwin, M. Vickers

{"title":"The role of systemic therapy in borderline resectable and locally advanced pancreatic ductal adenocarcinoma","authors":"V. Lo, R. Goodwin, M. Vickers","doi":"10.20517/2394-4722.2022.48","DOIUrl":"https://doi.org/10.20517/2394-4722.2022.48","url":null,"abstract":"Pancreatic ductal adenocarcinoma (PDAC) remains a deadly disease, even in patients whose cancer is localized and non-metastatic. Surgical resection provides the only option for cure, but long-term survival rates remain dismal. For patients with borderline resectable (BR) disease who undergo upfront resection, many patients are either too unwell for subsequent adjuvant systemic therapy, develop recurrence soon after, or are found to have unresectable disease intra-operatively. There is increasing evidence for a neoadjuvant approach, using more conventional multi-agent chemotherapy regimens, which have demonstrated higher activity in the metastatic setting compared to single agents. For patients with locally advanced (LA) disease, which is unresectable by current definitions, there is mounting evidence that effective neoadjuvant systemic therapy is able to convert some patients’ disease to a resectable state, offering the potential for long-term survival and cure. Herein we present a review of key trials focusing on prospective, randomized studies to provide high-level evidence supporting a neoadjuvant approach to both BR and LA PDAC. However, many knowledge gaps exist, such as the optimal neoadjuvant multi-agent chemotherapy regimen, the role of radiotherapy, and the safety and efficacy of adding immunotherapy to chemo/radiation therapy. Future challenges in determining the optimal approach to patients with BR or LA PDAC include not only overcoming the inherent difficulties in conducting complex, multidisciplinary, multicentre randomized trials in patients with a high-morbidity and mortality disease, but also trying to standardize disease definitions, treatment regimens, and outcome measures.","PeriodicalId":15167,"journal":{"name":"Journal of Cancer Metastasis and Treatment","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67652159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0